Strategic Partnerships VisCardia is actively engaged in clinical collaborations and showcases at major events such as EuroPCR 2025, indicating openness to partnerships, pilots, and potential co-development opportunities with hospitals, CROs, and device manufacturers.

Clinical Leadership Appointment of a Medical Affairs Director and ongoing clinical development of VisOne suggests a focus on clinical evidence generation and KOL engagement, creating opportunities for academic trials, guideline integrations, and targeted physician outreach.

Emerging Heart Failure Solution VisOne delivers synchronized diaphragmatic stimulation to augment hemodynamics, positioning VisCardia as a novel therapy for a large US and Europe heart failure patient base, with potential sales upside through early adopters and center-of-excellence programs.

Private Funding Readiness With funding around the mid-range and a revenue trajectory in the low-to-mid millions, there is room to pursue strategic investors or non-dilutive funding to accelerate clinical trials, regulatory approvals, and commercialization efforts.

Market Expansion Potential A compact team size (11-50 employees) paired with international clinical activity hints at scalable deployment through partnerships with distributors, contractmanufacturing, and targeted market-by-market entry strategies in Europe and the US.